Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Targeted Therapy
  •  Adjuvant Therapy
  •  Immunology
  •  Radiological Techniques and Scans
  •  Sarcomas
  •  Stomach Cancer
  •  Melanoma/Skin Cancer
  •  Central Nervous System Tumors

Abstract

Citation: Clin Oncol. 2022;7(1):1978.DOI: 10.25107/2474-1663.1978

Malignant Struma of the Ovary: Own Clinical Observation

Kiseleva MV, Denisov MS, Lunkova MN, Karibayeva ShK and Litvyakova EV

A. Tsyb Medical Radiological Research Center, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation (A. Tsyb MRRC) 249036, Russia
International Clinical Center of Reproductology PERSONA, Kazakhstan

*Correspondance to: Litvyakova Elena Viktorovna 

 PDF  Full Text Case Report | Open Access

Abstract:

Ovarian teratomas account for 15% to 20% of all ovarian tumors. Ovarian Struma (OS) in most cases (up to 50%) refers to monodermal mature ovarian teratoma and is a fairly rare tumor consisting of thyroid tissue. This type of neoplasm accounts for 1% of all ovarian tumors and 2.7% of all dermoid formations. The diagnosis of "ovarian struma" is made if the thyroid tissue is more than 50% of the tumor tissue. The article describes his own experience in managing a patient with a diagnosis of "Malignant struma of the ovary". Data on the clinical and morphological features of the disease are given.

Keywords:

Cite the Article:

Kiseleva MV, Denisov MS, Lunkova MN, Karibayeva ShK, Litvyakova EV. Malignant Struma of the Ovary: Own Clinical Observation. Clin Oncol. 2022;7:1978..

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Erlotinib Treatment Beyond Progression in EGFR Mutant Patients Who Have Responded to EGFR TKIs in Stage IIIB/IV NSCLC: An Open Label Randomized Trial
 Abstract  PDF  Full Text
Transanal vs. Laparoscopic Transabdominal Intersphincteric Resection for Lower Rectal Cancer: Comparison of the Operative and Functional Outcomes
 Abstract  PDF  Full Text
View More...